Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210

AMD11070 binds to the chemokine receptor CXCR4, with anti-HIV-1 activity in vitro and in vivo. We conducted a phase IB/IIA proof-of-concept dose-escalating, open-label study to determine safety and antiviral activity of AMD11070 administered over 10 days to HIV-1-infected participants who harbored C...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :AIDS Res Hum Retroviruses
Главные авторы: Johnson, Victoria A., Cramer, Yoninah S., Rosenkranz, Susan L., Becker, Stephen, Klingman, Karin L., Kallungal, Beatrice, Coakley, Eoin, Acosta, Edward P., Calandra, Gary, Saag, Michael S.
Формат: Artigo
Язык:Inglês
Опубликовано: Mary Ann Liebert, Inc., publishers 2019
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688111/
https://ncbi.nlm.nih.gov/pubmed/31099252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2018.0256
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы